Below are the speakers that presented at the 2016 Summit, their presentations are available in the resources section. 2017 speakers will be announced soon. If you would like to find out more please use the “Contact” page.
Executive Director, The Schroeder Institute for Tobacco Research and Policy Studies, Professor, The Johns Hopkins Bloomberg School of Public Health
David B. Abrams, PhD, is Executive Director of the Schroeder Institute for Tobacco Research and Policy Studies at Legacy. He is also a Professor in the Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health and Professor (Adjunct) at Georgetown University Medical Center/Lombardi Comprehensive Cancer Center. Previously, Dr. Abrams directed the Office of Behavioral and Social Sciences Research (OBSSR) at the National Institutes of Health. He holds a B.Sc. (honours) in Computer Science and Psychology from the University of Witwatersrand, South Africa, and a Doctorate in Clinical Psychology from Rutgers University, New Jersey. He has published over 250 scholarly articles. Dr. Abrams is author of The Tobacco Dependence Treatment Handbook: A Guide to Best Practices, a recipient of a book of the year award. He was President of the Society for Behavioral Medicine and received their Distinguished Scientist and Mentorship awards. Dr. Abrams also received the Joseph W. Cullen Memorial Award from the American Society for Preventive Oncology for lifetime contributions to tobacco control.
Dr. Abrams brings scientific expertise at the conceptual, basic, applied, policy and administrative levels. His current focus is on providing scientific leadership in tobacco control from a transdisciplinary perspective. Systems integration is arguably the single most critical missing ingredient needed to maximize the unrealized potential to reduce tobacco use prevalence. Specifically, he explores innovative ways to put what is known into widespread practice and policy to make an efficient impact on the population.
Recently, Dr. Abrams is focusing on the role research can play in informing policies for the regulation of tobacco products by the US Food and Drug Administration. This includes development of a strategic research agenda, convening content area experts, conducting knowledge synthesis and rapidly deploying research projects to address FDA mandates, such as whether mentholated cigarettes should remain on the market, evaluating the safety and consumer perceptions of e-cigarettes and tracking public perceptions of other potential and actual FDA regulations
Team Leader - Tobacco Control EU, Health and Wellbeing Division, Department of Health (DoH)
Alette works in the Tobacco Control Team at the Department of Health. She moved to the team in April this year to work on the transposition of European Directive 2014/40/EU, on the manufacture, presentation and sale of tobacco and related products, into UK law. The directive includes new regulatory provisions relating to e-cigarettes, which will be implemented in all Member States with the aim of harmonising the rules across the European Union.
Alette has a background in public health, beginning her career in local authorities before joining the civil service in 1997 where she has held a range of public health policy posts.
Competing interests: none stated
Chief Executive, Action on Smoking and Health (ASH)
Deborah Arnott is a recognised international expert on tobacco control and the WHO Framework Convention on Tobacco Control, with a particular interest in nicotine regulation and harm reduction. She was a member of the NICE Programme Development Group which developed the guidance on tobacco harm reduction and of the Commission on Human Medicines expert advisory group to the MHRA on nicotine containing products. She also has experience of product regulation under the EU General Product Safety Directive having participated in the development of fire safety requirements for cigarettes.
Deborah has an MBA from Cranfield, is an honorary Associate Professor at the University of Nottingham, and a member of the Royal College of Physicians Tobacco Advisory Group. She was awarded the Alwyn Smith prize in 2007 by the Faculty of Public Health for her outstanding contribution to public health.
Competing Interest: None Stated
Professor of Health Policy, University of Stirling, UK Centre for Tobacco and Alcohol Studies (UKTAS) and Cancer Research UK
Linda Bauld is Professor of Health Policy, Director of the Institute of Social Marketing and Dean of Research at the University of Stirling. She is also a Deputy Director of the UK Centre for Tobacco and Alcohol Studies and holds the Cancer Research UK/BUPA Chair in Behavioural Research for Cancer Prevention. She has conducted applied research on smoking and smoking cessation for 17 years and is a former scientific adviser on tobacco control for the UK government. She chaired the NICE programme development group on tobacco harm reduction and is involved in ongoing research on this topic.
Competing Interest: None Stated
Professor of Medicine and Bioengineering & Therapeutic Sciences, University of California, San Francisco
Neal L. Benowitz, MD, is Professor of Medicine and Bioengineering & Therapeutic Sciences, and Chief of the Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco (UCSF). He received his medical degree from the University of Rochester School of Medicine in 1969, following which he served as a resident in internal medicine at the Bronx Municipal Hospital Center from 1969 to 1971. He then completed a postdoctoral fellowship in clinical pharmacology at UCSF and joined the faculty in 1974. His research interests have focused primarily on the human pharmacology and toxicology of nicotine. He has published more than 500 research papers. Dr Benowitz also maintains an active clinical practice in cardiovascular medicine and medical toxicology.
Dr Benowitz was a scientific editor of the 1988 United States Surgeon General’s Report on Smoking and Health: Nicotine Addiction; a scientific editor of the 2001 NCI Monograph 13 Report on Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine; and served as section editor for the 2010 Surgeon General’s Report on How Tobacco Smoke Causes Disease. He,has served as a member of the National Institutes of Health Pharmacology Study Section, the FDA Nonprescription Drug Advisory Committee and the FDA Tobacco Products Science Advisory Committee. He is a member of a number of medical societies, including the American Society for Clinical Investigation and the Association of American Physicians. He has served as President of the American Society for Clinical Pharmacology and Therapeutics and as President of the Society for Research on Nicotine and Tobacco. Dr Benowitz has received the Ove Ferno, Alton Ochsner, and Rawls-Palmer Progress in Medicine awards, and the Oscar B. Hunter Memorial Award in Therapeutics for his research on nicotine, tobacco, and health, and was the 2002 UCSF Annual Distinguished Clinical Research Lecturer.
MD - Totally Wicked, Chair of IBVTA (Independent British Vape Trade Association)
Fraser Cropper is the Chair of IBVTA ( The Independent British Vape Trade Association) and Managing Director of Totally Wicked.
Founded by some of the UK’s leading independent manufacturers, importers, distributors, and vendors, IBVTA is a not-for-profit trade association representing all responsible and ethical independent vaping businesses in the UK irrespective of the size of their companies and operations. All IBVTA members are free from any control or ownership by the tobacco or pharmaceutical industries.
Based in the heart of Westminster, IBVTA is supported by a dedicated secretariat and a science and regulatory committee made up of engineers, chemists, and pharmacists.
The mission of IBVTA is to provide credible knowledge and guidance to support the independent vaping sector and promote constructive interaction between this industry sector and the scientific community, vapers, policy makers, and the general public. IBVTA fosters research and manufacturing excellence in order to deliver a robust yet proportionate consumer regulatory landscape that adequately reflects the needs of vaping stakeholders and recognises vaping as a sector in its own right.
Before working in industry Fraser served as a Commander in the Royal Navy. A Chartered Aeronautical Engineer, he spent 28 years in the navy serving in numerous operational, research and procurement roles.
Associate Professor of Psychology, School of Applied Sciences, London South Bank University
Dr Lynne Dawkins completed her PhD in 2001 and postdoctoral studies in 2006 in the School of Psychology at Goldsmiths College, London. She then took up a Senior Lectureship, and later, a Readership, in Psychology at the University of East London where she co-ordinated the Drugs and Addictive Behaviours Research Group. She moved to London South Bank University as an Associate Professor in Addictions in February 2016. Dr Dawkins has been conducting research in nicotine addiction and smoking cessation for nearly 20 years, focusing on acute, chronic and abstinence effects of nicotine on craving, cognition and reward motivation. Since 2009, she has focused on electronic cigarette research and has become one of the UK’s leading authorities on e-cigarettes. She has published extensively on e-cigarette use and nicotine delivery and disseminated her findings widely via academic conferences, public lectures and online media. She is a HEA Fellow, member of the Society for Nicotine and Tobacco Research, British Association of Psychophamacology, British Psychological Association and an Assistant Editor for the international journal Addition.
Stated Conflict of Interest:
LD has previously conducted research funded by e-cigarette companies and received honoraria for speaking at research conferences. She has no financial or non-financial interests in the e-cigarette industry. She has also acted as a consultant for the pharmaceutical industry. She has never received funding from the tobacco industry.
Tobacco Control Programme Lead, Publich Health England
Martin is Tobacco Control Programme Lead for Public Health England. He joined PHE in February after 7 years at Action on Smoking and Health. Martin has worked in Public Health since the mid 1980’s when he was involved in HIV prevention work. He is a fellow of the Royal Society of Public Health.
Professor of Public Health, University of Geneva
Professor Jean-François Etter (University of Geneva, Switzerland) has over 18 years of conducting smoking etiology, prevention and cessation research. He has published over 120 scientific articles on smoking cessation trials and various psychological questions related to tobacco dependence and smoking cessation.
He is an internationally known expert on e-cigarettes. He has published a comprehensive book on e-cigarettes, which was the first of its kind on the topic. In addition, he is credited with publishing some of the first scientific papers on e-cigarettes. His research has been crucial in shaping the initial understanding of the reasons and patterns of e-cigarette use.
Stated Conflicts of Interest: Professor Etter’s salary is paid by the University of Geneva, Switzerland. He never received any funding from the tobacco industry. He did not receive any funding from the pharmaceutical industry in the past 7 years. He was reimbursed by a manufacturer of e-liquids for traveling to London (in 2012) and to China (in 2013), but he was not paid for these meetings.
Research Fellow, Onassis Cardiac Surgery Greece, Department of Pharmacology, University of Patras, Greece
Konstantinos E. Farsalinos, M.D., is a research fellow at the Onassis Cardiac Surgery Center in Athens, Greece, and at the Department of Pharmacy, University of Patras, Greece. He has been conducting laboratory and clinical research on e-cigarettes as principle investigator since 2011. Examples of his work include the first study on the cytotoxic effects of e-cigarette vapor on cultured cells and the immediate effects of e-cigarette use on cardiac function and coronary circulation. He ran a worldwide online survey of almost 20,000 vapers (users of e-cigarettes) identifying patterns of use and experience with e-cigarettes among consumers, published in 2014. He has presented his research findings at major international scientific congresses and his research was used in preparing the regulatory framework on e-cigarettes by the European Union. As of 2016, he has published more than 40 studies and articles in international peer-reviewed scientific journals about smoking, tobacco harm reduction, and e-cigarettes
Competing Interest: For some of the studies, the institution has received funding from e-cigarette companies. None of the researchers received any compensation for participating to the studies.
Professor of Clinical Psychology, Queen Mary University of London
Peter Hajek is Professor of Clinical Psychology, Head of Psychology and Director of the Health and Lifestyle Research Unit at the Wolfson Institute of Preventative Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London. His research is concerned primarily with understanding health behaviours, and developing and evaluating both behavioural and pharmacological treatments for dependent smokers and for people with weight problems. He authored and co-authored over 300 publications on these topics.
I received research funding from and provided consultancy to manufacturers of stop-smoking medications. My research into safety and effects of EC is funded by NIHR, UKCTAS and MHRA. I have no links with any e-cigarette manufacturers.
Vaper - Board Member, New Nicotine Alliance
Since leaving school ‘a very long time ago’ Sarah Jakes has worked in the shipping industry, the foreign exchange market and now runs her own business in property management.
A smoker of some 35 years Sarah switched to vaping in April 2013, only to find that the choice of this safer alternative for smokers was under threat from excessive and ill founded regulation. Having joined forces with other consumers in the battle against over regulation in the EU parliament Sarah is convinced that a better understanding of e-cigarettes and other harm reduced products among key influencers and decision makers is required if these products are ever to reach their full potential for public health gains.
Vaper and Board Member, New Nicotine Alliance
Lorien Jollye is a mother of 3, an ex smoker of 23 years and a Vaper since 2012. After numerous, unsuccessful, quit attempts utilising most all the market had to offer, and smoking through two pregnancies, she found that e-cigarettes enabled her to switch her habit entirely, in one day. Since then, she has been a vocal advocate, volunteering with the Consumer Association and latterly, The New Nicotine Alliance, along with other passionate vapers. It has become a simple message, Nothing About Us Without Us.
E-cigarette Notification Scheme Lead, (MHRA) The Medicines and Healthcare Products Regulatory Agency
Beryl Keeley has a background in biochemistry and has worked in various areas in Government and previously in the pharmaceutical industry. Currently Beryl is Advertising Standards Unit Manager within the Vigilance and Risk Management of Medicines Division of the Medicines and Healthcare products Regulatory Agency. The Unit has responsibility for the regulation of medicines advertising in the UK. In this capacity Beryl has worked extensively to promote high standards in all medicines, and recently has been working with industry on the first product that fulfils the official definition of an e-cigarette to go through medicines licensing procedures and receive a marketing authorisation.
Beryl and the MHRA team are responsible for implementing the e-cigarette notification scheme and new regulatory framework under Article 20 of the Tobacco Products Directive. She brings experience in public perception and industry engagement around Nicotine Replacement Therapy and other medicines to the new functionality of MHRA in regulating e-cigarettes and consumer products. Understanding the clear and important differences between licensed NRT and the consumer products that make up the vast majority of the vaping industry serves an important purpose in Government plans for implementation and the introduction of a separate regulatory framework
PhD student - Drugs and Addictive Behaviours Research Group, University of East London, London, UK
Catherine Kimber is a PhD student at the School of Psychology at the University of East London. Her research is concerned with nicotine and smoking addiction with a focus on e-cigarette use. Earlier work looked at the relationship between e-cigarette types and their appeal to smokers. She has also been involved in other work which includes the effects of nicotine on smokers’ cognitive functioning. Her PhD is looking at compensatory behaviours in e-cigarette use, nicotine delivery and e-cigarettes’ efficacy as smoking cessation aids.
Scott J. Leischow, Ph.D. joined the Mayo Clinic in 2012, where he leads the Research on Health Equity and Community Health Program, and co-leads Cancer Prevention and Control within the Mayo Clinic Cancer Center. Dr Leischow is past President of the SRNT.
Dr Leischow is a behavioral scientist with expertise and interests in tobacco treatment and the role of social networks in the dissemination and implementation of evidence-based practices. His interests include optimal approaches for training health care providers on treating tobacco dependence, as well understanding how complex systems can be understood and optimized to foster improvements in health — particularly in underserved populations in the U.S. and globally.
- Investigating both pharmacological and behavioral treatments for tobacco dependence, including the exploration of dosing, adherence and the interplay of clinical and public health approaches
- Researching organizational networks to better understand how knowledge is spread and implementing practices that can lead to improvements in public health
Professor of Tobacco Addiction, UK Centre for Tobacco and Alcohol Studies (UKCTAS), Kings College London
Ann McNeill is a Professor of Addictions in the National Addiction Centre with a focus on tobacco. She graduated from the University of Nottingham with a first class joint honours degree in zoology and psychology and then carried out her PhD at the Institute of Psychiatry focusing on the development of dependence on smoking. Since that time she has held a variety of academic and public sector posts focusing largely on tobacco control research. Ann has an established international reputation, receiving a World Health Organisation award for contributions to tobacco control in 1998.
She has published more than 250 academic papers book chapters, reports and opinion pieces on the subject and her research ranges across prevention, cessation, harm reduction and local, national and international policy. Ann was a co-author of the recent systematic review of tobacco product packaging which underpinned the recent government consultation on plain packaging and has a particular interest in the relationship between smoking, mental health and inequalities. She is Deputy Director of the UK Centre for Tobacco Control Studies.
Competing Interest: None Stated
Attorney General of Iowa
Attorney General Tom Miller is serving in his ninth four-year term as Attorney General of Iowa. Tom Miller grew up in Dubuque, where his father was the long-time county assessor and an inspiration for Tom’s early interest in public service. He graduated from Wahlert High School in 1962 and Loras College in 1966, and received his law degree from Harvard Law School in 1969. Mr. Miller has earned a reputation for integrity, high quality legal work, and strong work on behalf of ordinary Iowans.
Attorney General Miller is known for his long-time fight on behalf of kids and taxpayers with his campaign to reduce the enormous death toll and financial costs of tobacco addiction and disease. He was a leader in the multistate settlement agreement that resulted in the tobacco industry paying billions of dollars to the states and changing the way it conducts business. Now Attorney General Miller is working to reduce youth addiction and the thousands of Iowans who die every year from tobacco-related disease.
Mr. Miller has a long record of achieving results through cooperation with other state attorneys general and with local, state and federal officials, regardless of their political affiliation. He has served as President of the National Association of Attorneys General (NAAG) and received NAAG’s Wyman Award as the attorney general who contributed most to NAAG and its members. He has chaired several NAAG committees and led major multistate working groups working on tobacco issues, antitrust enforcement, agriculture, and consumer protection.
“I consider it my duty and my privilege to be the people’s lawyer,” Attorney General Miller says. “I am deeply grateful for being able to serve as Attorney General of Iowa.”
Deputy Chair, BMA Board of Science (British Medical Association)
Mr Ram Moorthy is a Consultant ENT/Head & Neck Surgeon based at Wexham Park Hospital part of Frimley Health NHS Foundation Trust. He has an interest in medical education and training, and is the Associate Foundation School Director for Quality at Oxford Foundation School and a Foundation Training Programme Director. He has held various roles in the BMA (British Medical Association), including chair of its junior doctors committee, research grant supervisor and is a past member of its consultants committee. He is also deputy chair of the BMA board of science, and has taken a particular interest in tobacco policy and electronic cigarettes.
Senior Regulatory Policy Executive, Committee of Advertising Practice
Robert is responsible for advising the Committees of Advertising Practice (CAP) on a range of regulatory policy issues, many of which concern public health. In 2014 he project-managed the consultation and implementation of advertising rules for e-cigarettes and he will be running the scheduled review of those rules later in 2015. He joined CAP from the Advertising Standards Authority’s (ASA) investigations team where he was responsible for examining alleged breaches of the Advertising Codes. Prior to working in advertising regulation he worked as a producer on a range of investigative and consumer television programmes for the major broadcasters
Professor of Biological Psychology, University of Bristol, UK Centre for Tobacco and Alcohol Studies (UKTAS)
Marcus Munafò is Professor of Biological Psychology in the School of Experimental Psychology at the University of Bristol, and Director of the Tobacco and Alcohol Research Group (http://www.bristol.ac.uk/expsych/research/brain/targ/). His group is part of the UK Centre for Tobacco and Alcohol Studies, and the Medical Research Council Integrative Epidemiology Unit at the University of Bristol. His research focuses on understanding pathways into, and the consequences of, health behaviours and mental health, with a particular focus on tobacco and alcohol use. This work includes: 1) observational and genetic epidemiology, and the use of a range of methods that enable stronger causal inference from observational data, such as negative control and Mendelian randomization methods; 2) the laboratory study of cognitive and neurobiological mechanistic pathways that underpin exposure-outcome relationships; and 3) the development of novel individual- and population-level interventions that target these mechanisms, including choice architecture interventions.
Managing Director, ECigIntelligence.com
Tim is a founder and managing director of ECigIntelligence. He is a UK-qualified attorney, having worked at the European Commission, BSkyB and Herbert Smith (an international law firm), AOL Europe, as director of public affairs at Betfair (IPO in 2010 valued at £1.5bn), and as a partner in a New York VC-funded startup in the diamond sector. Tim holds a Postgraduate Diploma in Legal Practise from the University of Law, London and a Masters in Geology from Oxford University
Director, Institute of Internal Medicine and Clinical Immunology, University of Catania
Professor Riccardo Polosa is Director of the Institute for Internal and Emergency Medicine of the University of Catania in Italy. He is also in charge of the University’s Centre for Tobacco Research (CPCT), and Honorary Professor of Medicine at Southampton University (UK). He is author of more than 250 peer reviewed articles and books mainly covering repiratory medicine, clinical immunology, and tobacco addiction. Professor Polosa and his research team have lead several clinical trials on e-cigarettes.
On top of his academic work, he serves also as Chief Scientific Advisor for Lega Italiana Anti Fumo (LIAF), the Italian Anti-Smoking League.
CONFLICT OF INTERESTS:
Riccardo Polosa has received lecture fees and research funding from GlaxoSmithKline and Pfizer, manufacturers of stop smoking medications.
He has also served as a consultant for Pfizer and Arbi Group Srl (Milano, Italy), the distributor of Categoria™ e-Cigarettes. His research on electronic cigarettes is currently supported by LIAF (Lega Italiana AntiFumo).
Stop Smoking Service Manager, Leicester City Council
Louise Ross is the Stop Smoking Service Manager for Leicester City. She has worked in smoking cessation and tobacco control for ten years. Previously she had managed a large care home for people with learning disabilities for almost 30 years, and this career change, an opportunity that disproves the theory that one needs a life-plan to be happy, has been a fantastic opportunity to influence people’s health for the better.
Initially suspicious of e-cigs, her epiphany moment happened at the 2013 E-Cigarette Summit (around lunchtime), and since then she has been a committed advocate of listening to what the general public, and Stop service users in particular, are saying about their experiences of vaping.
Competing Interest Louise has not personally received any funding from external sources but Leicester Stop Smoking Service has received contributions from GSK, Pfizer, Johnson & Johnson for example in terms of training lunches for Level 2 advisors.
Winton Professor of the Public Understanding of Risk, Cambridge University
David Spiegelhalter is the Winton Professor for the Public Understanding of Risk, and Professor of Biostatistics, at the University of Cambridge. His background is in medical statistics, particularly the use of Bayesian methods in clinical trials, health technology assessment and drug safety. In 2014 he was awarded a Knighthood for services to statistics.
David Spiegelhalter is a statistician who has pioneered the modelling of risk in medical contexts. He has brought statistical methodology into the heart of clinical performance monitoring and has worked extensively to improve general understanding of mathematical uncertainty. In his post he leads a small team (UnderstandingUncertainty.org) that attempts to improve the way in which the quantitative aspects of risk and uncertainty are discussed in society
An expert on medical statistics, David has played a leading role in a number of public inquiries and was part of the Joint British Societies team that developed revised guidelines for cardiovascular care. He is also a popular and respected communicator of scientific concepts and has written numerous books and newspaper articles explaining the nature of risk, uncertainty and statistics.
He has over 190 refereed publications and is co-author of 6 textbooks, as well as The Norm Chronicles (with Michael Blastland). He is an Honorary Fellow of the Institute for Risk Management, an Honorary Fellow of The Royal College of Physicians, was elected Fellow of the Royal Society in 2005 and awarded an OBE in 2006 for services to medical statistics.
Professor of Health Psychology & Director of Tobacco Studies, University College London (UCL)
Robert West is Professor of Health Psychology and Director of Tobacco Studies at the Cancer Research UK Health Behaviour Research Centre, University College London, UK. Professor West is also Editor-in-Chief of the journal Addiction. He is co-author of the English National Smoking Cessation Guidelines that provided the blueprint for the UK-wide network of stop-smoking services that are now an established part of the UK National Health Service. His research includes evaluations of methods of helping smokers to stop and population surveys of smoking and smoking cessation patterns.
I undertake research and consultancy for companies that develop and manufacture smoking cessation medications including licensed nicotine products. I am author of the stop-smoking guide ‘The SmokeFree Formula’. My salary is funded by Cancer Research UK.